Two abstracts accepted for the American Association of Cancer Research 2020 (AACR 2020) has now been published online.
The first study entitled “Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during 5-fluoruracil treatment.” by Jagarlamudi KK et al, has been accepted for presentation at the AACR virtual congress June 22-24. This study demonstrates how the immunoassay of Thymidine Kinase 1 can be used to study anti-cancer drug effects in a clinically relevant model. It can be accessed following the Link.
The second abstract for the poster that is entitled “Serum Thymidine Kinase 1 levels predict prostate cancer-specific survival” and is based on a study by Teemu Murtola of Tampere University Hospital. On the use of Thymidine Kinase 1 as a marker for the risk of prostate cancer progression after diagnosis, can be accessed here, Länk.
